ALI GRIFFIN: Open Payments
NPI 1144643669 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,767 in 154 payments from 19 companies in 2025. Trend: 2023 $2,220 · 2024 $2,250 · 2025 $3,767
Food & beverage: $3,767
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $707 |
| Madrigal Pharmaceuticals | 16 | $599 |
| GENZYME CORPORATION | 8 | $266 |
| QOL Medical, LLC | 8 | $264 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $246 |
| Janssen Biotech, Inc. | 13 | $246 |
| Phathom Pharmaceuticals, Inc. | 11 | $242 |
| Ardelyx, Inc. | 6 | $236 |
| Lilly USA, LLC | 6 | $144 |
Products named: REZDIFFRA, DUPIXENT, SKYRIZI, Sucraid, XIFAXAN, TREMFYA, VOQUEZNA, IBSRELA.
Industry payments across MD — which companies pay providers there.
